← Back to Search

Virus Therapy

Open Label for Breast Cancer

Phase 2
Waitlist Available
Led By Steven J Isakoff, MD PhD
Research Sponsored by Rogers Sciences Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically or cytologically confirmed Stage IIIb or IV breast cancer with cutaneous metastases.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 23
Awards & highlights

Study Summary

The purpose of this Phase II study is to evaluate the efficacy and safety of Continuous Low- Irradiance Photodynamic Therapy (CLIPT) when used with Verteporfin in the treatment of cutaneous metastases of breast cancer for which no curative or significantly palliative therapy exists, including chest wall therapy.

Eligible Conditions
  • Breast Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 23
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 23 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Objective Response Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Open LabelExperimental Treatment2 Interventions
Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Verteporfin
FDA approved

Find a Location

Who is running the clinical trial?

Rogers Sciences Inc.Lead Sponsor
3 Previous Clinical Trials
30 Total Patients Enrolled
1 Trials studying Breast Cancer
3 Patients Enrolled for Breast Cancer
Steven J Isakoff, MD PhDPrincipal InvestigatorMassachusetts General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
2016. "An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02939274.
All > Bone Metastases
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top